Last reviewed · How we verify
SDD Oral Paste
SDD Oral Paste is a drug that targets the SGLT2 receptor.
SDD Oral Paste is a drug that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | SDD Oral Paste |
|---|---|
| Also known as | Colistin, Tobramycin and Nystatin |
| Sponsor | The George Institute |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors like SDD Oral Paste work by blocking the reabsorption of glucose in the kidneys, thereby reducing blood glucose levels. This can lead to weight loss and improved cardiovascular outcomes in patients with type 2 diabetes. By inhibiting SGLT2, SDD Oral Paste helps to lower blood glucose levels and improve glycemic control.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (PHASE3)
- Ecological Effects of Decolonisation Strategies in Intensive Care (PHASE3)
- SDD for Eradicating CRKP Carriage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |